Clinical and laboratory factors that affect the post-transfusion platelet increment

Transfusion of platelet concentrates (PC) reduced the incidence of fatal hemorrhages in several thrombocytopenic conditions. Unfortunately, long-term platelet supportive care may be complicated by the development of a state of refractoriness, resulting in inadequate recovery of functional platelets....

Full description

Saved in:
Bibliographic Details
Published in:Transfusion science 2000-08, Vol.23 (1), p.63-68
Main Authors: Fabris, F., Soini, B., Sartori, R., Randi, M.L., Luzzatto, G., Girolami, A.
Format: Article
Language:English
Subjects:
Adult
Aged
Anti-HLA antibodies
Anti-HPA antibodies
Bleeding Time
Blood Platelets - pathology
Blood Platelets - physiology
Female
Health technology assessment
HLA Antigens - immunology
Humans
Isoantigens - immunology
Male
Middle Aged
Platelet concentrates
Platelet Transfusion - adverse effects
Post-transfusion platelet increment
Prospective Studies
Thrombocytopenia - immunology
Thrombocytopenia - physiopathology
Thrombocytopenia - therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Transfusion of platelet concentrates (PC) reduced the incidence of fatal hemorrhages in several thrombocytopenic conditions. Unfortunately, long-term platelet supportive care may be complicated by the development of a state of refractoriness, resulting in inadequate recovery of functional platelets. PC handling, clinical conditions of the patients and alloimmunization are the main factors affecting refractoriness. We evaluated the post-transfusion platelet increase in 25 patients (M=6, F=19) with hypomegakaryocytic thrombocytopenia receiving random ABO-compatible PC within 24 h after collection. Quality of PC was assessed by platelet count, pH measuring, LDH release, glycocalicin levels, CD-62 and CD-42b expression. Besides history, clinical status and therapy, we searched for the presence of anti-HLA class 1 and anti-HPA 1-4-5 antibodies. Only six patients (24%) were refractory to PC transfusion, as assessed by a corrected count increment (CCI)
ISSN:0955-3886
1879-3126
DOI:10.1016/S0955-3886(00)00064-3